Positive and negative roles of IL-6, STAT3, and SOCS3 in inflammatory arthritis

Advances in Experimental Medicine and Biology

Volumn 602, Issue , 2007, Pages 113-124

  Kinjyo, Ichiko ^a   Ohishi, Masanobu ^a   Shouda, Takanori ^a   Kobayashi, Takashi ^a   Yoshimura, Akihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; SOCS3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING; UNCLASSIFIED DRUG;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MODEL; FIBROBLAST; GENE OVEREXPRESSION; GENE TARGETING; MACROPHAGE; MOUSE STRAIN; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; TH17 CELL; TH3 CELL; ANIMAL; ARTICLE; BONE DEVELOPMENT; HUMAN; METABOLISM; MOUSE;

ANIMALS; ARTHRITIS, RHEUMATOID; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; MICE; OSTEOGENESIS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 38449117957     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72009-8_15     Document Type: Conference Paper

References (29)

1. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996a. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440.
2. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996b. Rheumatoid arthritis. Cell 85(3): 307-310.
3. Elliott, M.J., R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane, H. Biji, et al. 1994. Randomiced double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (8930): 1105-1110.
4. Elliott, M.J., R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, H. Biji, and J.N. Woody. 1994. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344(8930): 1125-1127.
5. Mihara, M., Y. Moriya, T. Kishimoto, and Y. Ohsugi. 1995. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 34(4): 321-325.
6. Tamura, T., N. Udagawa, N. Takahashi, C. Miyaura, S. Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki, T. Taga, et al. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90(24): 11924-11928.
7. Boe, A., M. Baiocchi, M. Carbonatto, R. Papoian, and O. Serlupi-Crescenzi. 1999. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11(12): 1057-1064.
8. Ohshima, S., Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, et al. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95(14): 8222-8226.
9. Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187(4): 461-468.
10. Yoshizaki, K., N. Nishimoto, M. Mihara, and T. Kishimoto. 1998. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Serum Immunopathol 20(1-2): 247-259.
11. Shouda, T., T. Yoshida, T. Hanada, T. Wakioka, M. Oishi, K. Miyoshi, S. Komiya, K. Kosai, Y. Hanakawa, K. Hashimoto, K. Nagata, and A. Yoshimura. 2001. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 108(12): 1781-1788.
12. Atsumi, T., et al. 2002. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 196(7): 979-990.
13. Hirano, T., K. Ishihara, M. Hibi. 2000. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.Oncogene 19(21): 2548-2556.
14. Xu, Q., J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G.L. Semenza, J.Q. Cheng, R. Jove, and H. Yu. 2005. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.Oncogene 24(36): 5552-5560.
15. Ogata, H., T. Chinen, T. Yoshida, I. Kinjyo, G. Takaesu, H. Shiraishi, M. Iida, T. Kobayashi, A. Yoshimura. 2006. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 25(17): 2520-2530.
16. O'Brien, C.A., et al. 1999. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274(27): 19301-19308.
17. Kubo, M., T. Hanada, and A. Yoshimura. 2003. Suppressors of cytokine signaling and immunity. Nat Immunol 4(12): 1169-1176.
18. Yoshimura, A., H. Nishinakamura, Y. Matsumura, and T. Hanada. 2005. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 7(3): 100-110.
19. Takeda, K., et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10(1): 39-49.
20. Yasukawa, H., et al. 2003. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4(6): 551-556.
21. Lang, R., et al. 2003. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4(6): 546-550.
22. Croker, B.A., et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4(6): 540-545.
23. Hayashi, T., T. Kaneda, Y. Toyama, M. Kumegawa, and Y. Hakeda. 2002. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem 277(31): 27880-27886.
24. Clausen, B.E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Forster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8(4): 265.
25. Ohishi, M., Y. Matsumura, D. Aki, R. Mashima, K. Taniguchi, T. Kobayashi, T. Kukita, Y. Iwamoto, and A. Yoshimura. 2005. Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines. J Immunol 174(5): 3024-3031.
26. Takayanagi, H., K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokochi, H. Oda, K. Tanaka, K. Nakamura, and T. Taniguchi. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408(6812): 600-605.
27. Seki, Y., H. Inoue, N. Nagata, K. Hayashi, S. Fukuyama, K. Matsumoto, O. Komine, S. Hamano, K. Himeno, K. Inagaki-Ohara, N. Cacalano, A. O'Garra, T. Oshida, H. Saito, J.A. Johnston, A. Yoshimura, and M. Kubo. 2003. SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses. Nat Med 9(8): 1047-1054.
28. Kinjyo, I., H. Inoue, S. Hamano, S. Fukuyama, T. Yoshimura, K. Koga, H. Takaki, K. Himeno, G. Takaesu, T. Kobayashi, and A. Yoshimura. 2006. Related Articles, Links Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 203(4): 1021-1031.
29. Chen, Z., A. Laurence, Y. Kanno, M. Pacher-Zavisin, B.M. Zhu, C. Tato, A. Yoshimura, L. Hennighausen, and J.J. O'Shea. 2006. Related Articles, Links Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103(21): 8137-8142.